Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Anti-EBV VCA highest quartile status, anti-EBV EBNA-1 highest quartile status, HLA DRB1*1501 positivity, active smoking status and vitamin D deficiency status were not associated with the number of relapses (all p>0.26), progression to CDMS (all p>0.44) or time to first relapse (all p-values >0.41).
Source: Associations of Other Factors with Relapses. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
All patients were treated with interferon-beta.
Source: Abstract.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Environmental Factors Associated with Disease Progression after the First Demyelinating Event: Results from the Multi-Center SET Study
Study design awaiting verification · PLoS ONE · 2013
Original publication title
Environmental Factors Associated with Disease Progression after the First Demyelinating Event: Results from the Multi-Center SET Study
© 2013 Horakova et al
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What objectives does the paper state?
To investigate the associations of environmental MS risk factors with clinical and MRI measures of progression in high-risk clinically isolated syndromes (CIS) after the first demyelinating event.
Source: ObjectivesAbstract: What methods does the paper describe?
We analyzed 211 CIS patients (age: 28.9±7.8 years) enrolled in the SET study, a multi-center study of high-risk CIS patients. Pre-treatment samples were analyzed for IgG antibodies against cytomegalovirus (anti-CMV), Epstein Barr virus (EBV) early nuclear antigen-1 (EBNA-1), viral capsid antigen (VCA), early antigen-diffuse (EA-D), 25 hydroxy-vitamin D3 and cotinine levels and HLA DRB1*1501 status. The inclusion criteria required evaluation within 4 months of the initial demyelinating event, 2 or more brain MRI lesions and the presence of two or more oligoclonal bands in cerebrospinal fluid.
All patients were treated with interferon-beta. Clinical and MRI assessments were obtained at baseline, 6, 12, and 24 months.
Source: MethodsAbstract: Results
The time to first relapse decreased and the number of relapses increased with anti-CMV IgG positivity. Smoking was associated with increased number and volume of contrast-enhancing lesions (CEL) during the 2-year period. The cumulative number of CEL and T2 lesions during the 2-year period was greater for individuals in the highest quartile of anti-EBV VCA IgG antibodies. The percent loss of brain volume was increased for those in the highest quartile of with anti-EBV VCA IgG antibodies.
Source: ResultsAbstract: Conclusions
Relapses in CIS patients were associated with CMV positivity whereas anti-EBV VCA positivity was associated with progression on MRI measures, including accumulation of CEL and T2 lesions and development of brain atrophy.
Source: ConclusionsAuthors’ abstract
Objectives
To investigate the associations of environmental MS risk factors with clinical and MRI measures of progression in high-risk clinically isolated syndromes (CIS) after the first demyelinating event.
Methods
We analyzed 211 CIS patients (age: 28.9±7.8 years) enrolled in the SET study, a multi-center study of high-risk CIS patients. Pre-treatment samples were analyzed for IgG antibodies against cytomegalovirus (anti-CMV), Epstein Barr virus (EBV) early nuclear antigen-1 (EBNA-1), viral capsid antigen (VCA), early antigen-diffuse (EA-D), 25 hydroxy-vitamin D3 and cotinine levels and HLA DRB1*1501 status. The inclusion criteria required evaluation within 4 months of the initial demyelinating event, 2 or more brain MRI lesions and the presence of two or more oligoclonal bands in cerebrospinal fluid.
All patients were treated with interferon-beta. Clinical and MRI assessments were obtained at baseline, 6, 12, and 24 months.
Results
The time to first relapse decreased and the number of relapses increased with anti-CMV IgG positivity. Smoking was associated with increased number and volume of contrast-enhancing lesions (CEL) during the 2-year period. The cumulative number of CEL and T2 lesions during the 2-year period was greater for individuals in the highest quartile of anti-EBV VCA IgG antibodies. The percent loss of brain volume was increased for those in the highest quartile of with anti-EBV VCA IgG antibodies.
Conclusions
Relapses in CIS patients were associated with CMV positivity whereas anti-EBV VCA positivity was associated with progression on MRI measures, including accumulation of CEL and T2 lesions and development of brain atrophy.
Publication and source details
Original title: Environmental Factors Associated with Disease Progression after the First Demyelinating Event: Results from the Multi-Center SET Study
Dana Horakova; Robert Zivadinov; Bianca Weinstock-Guttman; Eva Havrdova; Jun Qu; Miriam Tamaño-Blanco; Darlene Badgett; Michaela Tyblova; Niels Bergsland; Sara Hussein; Laura Willis; Jan Krasensky; Manuela Vaneckova; Zdenek Seidl; Petra Lelkova; Michael G. Dwyer; Ming Zhang; Haoying Yu; Xiaotao Duan; Tomas Kalincik; Murali Ramanathan
PLoS ONE · 2013
* E-mail: Murali@Buffalo.eduCompeting Interests: Dr. Dana Horakova received speaker honoraria and consultant fees from Biogen Idec, Novartis, Merck Serono, Teva and Bayer Schering and financial support for research activities from Biogen Idec. The SET study is an investigator-initiated study supported by Biogen Idec Inc. Dr. Zivadinov has received speaker honoraria and consultant fees from Teva Neurosciences, Biogen Idec, Questcor, Genzyme-Sanofi, Novartis, Bracco, Bayer and EMD Serono. He has received research support from the National Multiple Sclerosis Society, Department of Defense, Biogen Idec, Teva Neuroscience, Teva Pharmaceuticals, EMD Serono, Genzyme-Sanofi, Questcor, Bracco and Greatbatch.
Dr. Weinstock-Guttman received honoraria for serving in advisory boards and educational programs from Teva Neuroscience, Biogen Idec, Novartis, Accorda EMD Serono, Pfizer, Novartis, Genzyme and Sanofi. She also received support for research activities from the National Institutes of Health, National Multiple Sclerosis Society, National Science Foundation, Department of Defense, EMD Serono, Biogen Idec, Teva Neuroscience, Cyberonics, Novartis, Acorda and the Jog for the Jake Foundation. Dr. Eva Havrdova received honoraria and consulting fees from Genzyme, Biogen Idec, Sanofi-Aventis, Merck Serono, Roche, Teva and Novartis for consulting services, speaking and serving on a scientific advisory boards.
Dr. Jun Qu received research funding from the Department of Defense, the National Science Foundation, the National Institutes of Health, the American Heart Association, Kinex, CH3, Pfizer, Novartis, Abbott and Amgen. These are unrelated to the research presented in this report. Drs. Michaela Tyblova, Jan Krasensky, Manuela Vaneckova, and Zdenek Seidl have received financial support for research activities from Biogen Idec. Dr. Petra Lelkova has no conflicts to disclose. Dr. Tomas Kalincik received compensation for travel and honoraria from Novartis, Biogen Idec, Sanofi Aventis, Teva and Merck Serono.
Dr. Murali Ramanathan received research funding or consulting fees from EMD Serono, Biogen Idec, Allergan, Netezza, Pfizer, Novartis, Monsanto the National Multiple Sclerosis Society, the Department of Defense, Jog for the Jake Foundation, the National Institutes of Health and National Science Foundation. He received compensation for serving as an Editor from the American Association of Pharmaceutical Scientists. These are unrelated to the research presented in this report. Miriam Tamaño-Blanco, Darlene Badgett, Niels Bergsland, Sara Hussein, Laura Willis, Michael G. Dwyer, Haoying Yu, Ming Zhang and Xiaotao Duan have no conflicts to disclose.
This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.
Conceived and designed the experiments: DH EH ZS MV BWG JQ RZ MR. Performed the experiments: MTB DB MT PL NB SH LW JK MGD MZ HY XD. Analyzed the data: MR RZ TK. Wrote the paper: MR BWG DH EH TK RZ.
Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-12T13:24:11.112054+00:00
DOI: 10.1371/journal.pone.0053996 · PMC3540021